pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.
Company profile
Ticker
PACB
Exchange
Website
CEO
Christian O. Henry
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NANOFLUIDICS INC, PACIFIC BIOSCIENCES OF CALIFORNIA INC
SEC CIK
Corporate docs
Subsidiaries
Pacific Biosciences International LLC • Pacific Biosciences Canada Limited • Pacific Biosciences Germany GmbH • Pacific Biosciences (Shanghai) Co., Ltd. • PacBio Singapore Pte. Limited • Pacific Biosciences UK, Ltd. • Omniome, LLC • Circulomics Inc. • PacBio B.V. • Apton Biosystems LLC ...
IRS number
161590339
PACB stock data
Latest filings (excl ownership)
8-K
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
16 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
POSASR
Automatic shelf registration (post-effective amendment)
11 Apr 24
POSASR
Automatic shelf registration (post-effective amendment)
11 Apr 24
POSASR
Automatic shelf registration (post-effective amendment)
11 Apr 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
PacBio Announces Fourth Quarter and Fiscal Year 2023 Financial Results
15 Feb 24
8-K
PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively
8 Jan 24
8-K
Departure of Directors or Certain Officers
11 Dec 23
Transcripts
PACB
Earnings call transcript
2023 Q4
15 Feb 24
PACB
Earnings call transcript
2023 Q3
30 Oct 23
PACB
Earnings call transcript
2023 Q2
2 Aug 23
PACB
Earnings call transcript
2023 Q1
2 May 23
PACB
Earnings call transcript
2022 Q4
16 Feb 23
PACB
Earnings call transcript
2022 Q3
7 Nov 22
PACB
Earnings call transcript
2022 Q2
4 Aug 22
PACB
Earnings call transcript
2022 Q1
5 May 22
PACB
Earnings call transcript
2021 Q4
16 Feb 22
PACB
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
KATHY ORDONEZ
19 Mar 24
4
David W Meline
6 Mar 24
4
Michele Farmer
6 Mar 24
4
Oene Mark Van
6 Mar 24
4
Susan G. Kim
6 Mar 24
4
CHRISTIAN O HENRY
6 Mar 24
4
MARSHALL MOHR
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 388.37 mm | 388.37 mm | 388.37 mm | 388.37 mm | 388.37 mm | 388.37 mm |
Cash burn (monthly) | (no burn) | (no burn) | 27.50 mm | 27.83 mm | 21.73 mm | 21.85 mm |
Cash used (since last report) | n/a | n/a | 188.96 mm | 191.27 mm | 149.31 mm | 150.14 mm |
Cash remaining | n/a | n/a | 199.41 mm | 197.10 mm | 239.06 mm | 238.23 mm |
Runway (months of cash) | n/a | n/a | 7.3 | 7.1 | 11.0 | 10.9 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Ordonez Kathy | Common Stock | Option exercise | Acquire M | No | No | 2.63 | 37,106 | 97.59 k | 380,216 |
15 Mar 24 | Ordonez Kathy | Common Stock | Option exercise | Acquire M | No | No | 2.9 | 324,515 | 941.09 k | 343,110 |
15 Mar 24 | Ordonez Kathy | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.63 | 37,106 | 97.59 k | 0 |
15 Mar 24 | Ordonez Kathy | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.9 | 324,515 | 941.09 k | 0 |
6 Mar 24 | Meline David W | Common Stock | Buy | Acquire P | No | No | 4.404 | 40,000 | 176.16 k | 40,000 |
4 Mar 24 | Van Oene Mark | Common Stock | Sell | Dispose S | No | No | 4.871 | 9,186 | 44.75 k | 1,668,826 |
4 Mar 24 | Susan G. Kim | Common Stock | Sell | Dispose S | No | No | 4.871 | 5,275 | 25.69 k | 712,260 |
4 Mar 24 | Henry Christian O | Common Stock | Sell | Dispose S | No | No | 4.871 | 14,177 | 69.06 k | 2,596,670 |
News
JP Morgan Downgrades Pacific Biosciences to Neutral
22 Apr 24
Bernstein Maintains Outperform on Pacific Biosciences, Lowers Price Target to $2.5
18 Apr 24
Goldman Sachs Downgrades Pacific Biosciences to Neutral, Lowers Price Target to $2.5
18 Apr 24
Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $8
18 Apr 24
A Glimpse Into The Expert Outlook On Pacific Biosciences Through 4 Analysts
17 Apr 24
Press releases
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
16 Apr 24
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes
27 Mar 24
PacBio Grants Equity Incentive Award to New Employee
22 Mar 24
Experiential Marketing Firm VOLO Events Agency Wins Best Event Technology Award for PacBio Product Launch
13 Feb 24
PacBio Announces HiFi Prep Kit 96 and HiFi Plex Prep Kit 96 for Long-Read Sequencing Applications at Scale
5 Feb 24